Bioadaptives, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OID
BioAdaptives reports a net loss of $111,086 for Q1 2026 while continuing to face substantial doubt regarding its ability to continue as a going concern.
OID
BioAdaptives Inc. reported increased revenue in Q3 2025 driven by new product launches, but also saw a significant rise in net loss and faces substantial doubt about its ability to continue as a going concern.
OID
BioAdaptives Inc. reported a significant decline in revenue and increased operating expenses, raising substantial doubt about its ability to continue as a going concern.
OID
BioAdaptives Inc. reports a net loss for Q1 2025, but anticipates revenue growth with upcoming product launches and strategic marketing initiatives.
OID
BioAdaptives Inc. reported a net loss of $527,373 for the nine months ended September 30, 2024, an increase from the $444,165 loss in the same period of 2023, alongside ongoing concerns about its ability to continue as a going concern.
OID
BioAdaptives Inc. reports a widened net loss for the second quarter of 2024, impacted by increased operating expenses and cost of revenue, as the company reformulates its product line and explores new market opportunities.
OID
BioAdaptives Inc. saw a significant increase in revenue for the first quarter of 2024 compared to the same period last year, but the company continues to operate at a loss.